Paloma Health Features Amerithroid™ in Coverage of Its U.S. Launch
RIDGEWOOD, NJ — JULY 17, 2026 — Paloma Health, a digital health platform serving patients with hypothyroidism, has featured Amerithroid™ (Thyroid Tablets, USP) in an article covering its commercial launch. The piece was written by thyroid patient advocate and author Mary Shomon and was last updated on July 15, 2026.
The article introduces Amerithroid as a natural desiccated thyroid (NDT) medication containing both T4 and T3 hormones derived from porcine thyroid glands, manufactured domestically in an FDA-inspected facility using U.S.-sourced ingredients. It walks readers through the eight available dosage strengths (15–300 mg), batch testing against USP standards, full ingredient traceability, the identifiable Oliva leaf pill imprint, and “Dispense As Written” (DAW) protection against pharmacy substitution. It also notes that Amerithroid is covered by many insurance plans, with copay assistance available.
The article quotes Daniel Akeson, Chief Executive Officer of Oliva Therapeutics: “The launch of Amerithroid is years in the making and builds on my family’s deep connection to patients with hypothyroidism and our commitment to quality U.S. manufacturing of pharmaceutical products.”
Coverage also highlights that Oliva Therapeutics is committed to pursuing FDA approval for Amerithroid and is actively planning and investing for the regulatory future.
Read the full article on Paloma Health:
https://www.palomahealth.com/learn/amerithroid-american-made-natural-desiccated-thyroid-drug-ndt
More information on Amerithroid can be found at www.amerithroid.com.
